CoChat

Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type

Open access
Rust, Steven, Guillard, Sandrine, Sachsenmeier, Kris, Hay, Carl, Davidson, Max, Karlsson, Anders, Karlsson, Roger, Brand, Erin, Lowne, David, Elvin, John, Flynn, Matt, Kurosawa, Gene, Hollingsworth, Robert, Jermutus, Lutz, Minter, Ralph · 2013 · Molecular Cancer
Cited by 51

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The continued discovery of therapeutic antibodies, which address unmet medical needs, requires the continued discovery of tractable antibody targets. Multiple protein-level target discovery approaches are available and these can be used in combination to extensively survey relevant cell membranomes. In this study, the MDA-MB-231 cell line was selected for membranome survey as it is a 'triple negative' breast cancer cell line, which represents a cancer subtype that is aggressive and has few treatment options. METHODS: The MDA-MB-231 breast carcinoma cell line was used to explore three membranome target discovery approaches, which were used in parallel to cross-validate the significance of identified antigens. A proteomic approach, which used membrane protein enrichment followed by protein identification by mass spectrometry, was used alongside two phenotypic antibody screening approaches. The first phenotypic screening approach was based on hybridoma technology and the second was based on phage display technology. Antibodies isolated by the phenotypic approaches were tested for cell specificity as well as internalisation and the targets identified were compared to each other as well as those identified by the proteomic approach. An anti-CD73 antibody derived from the phage display-based phenotypic approach was tested for binding to other 'triple negative' breast cancer cell lines and tested for tumour growth inhibitory activity in a MDA-MB-231 xenograft model. RESULTS: All of the approaches identified multiple cell surface markers, including integrins, CD44, EGFR, CD71, galectin-3, CD73 and BCAM, some of which had been previously confirmed as being tractable to antibody therapy. In total, 40 cell surface markers were identified for further study. In addition to cell surface marker identification, the phenotypic antibody screening approaches provided reagent antibodies for target validation studies. This is illustrated using the anti-CD73 antibody, which bound other 'triple negative' breast cancer cell lines and produced significant tumour growth inhibitory activity in a MDA-MB-231 xenograft model. CONCLUSIONS: This study has demonstrated that multiple methods are required to successfully analyse the membranome of a desired cell type. It has also successfully demonstrated that phenotypic antibody screening provides a mechanism for rapidly discovering and evaluating antibody tractable targets, which can significantly accelerate the therapeutic discovery process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-12-11

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 14

  1. 10.1038/nrd2241 · DOI · Paper page
  2. 10.1016/j.bbagen.2005.09.017 · DOI
  3. 10.1677/erc.1.00766 · DOI
  4. 10.1073/pnas.0712202105 · DOI
  5. 10.1007/s10549-010-1293-1 · DOI · Paper page
  6. 10.1074/jbc.273.21.13047 · DOI · Paper page
  7. 10.1172/JCI45014 · DOI · Paper page
  8. 10.1038/bjc.2012.212 · DOI
  9. 10.1074/jbc.M602547200 · DOI
  10. 10.1038/bjc.1991.23 · doi:10.1038/bjc.1991.23
  11. 10.1073/pnas.0908801107 · DOI · Paper page
  12. 10.1038/nbt0396-309 · DOI · Paper page
  13. 10.1089/hyb.1997.16.381 · DOI
  14. 10.1038/256495a0 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Rust, S., Guillard, S., Sachsenmeier, K., Hay, C., Davidson, M., Karlsson, A., Karlsson, R., Brand, E., Lowne, D., Elvin, J., Flynn, M., Kurosawa, G., Hollingsworth, R., Jermutus, L., & Minter, R.
Venue
Molecular Cancer
Published
2013
Volume
12
Issue
1
Pages
11
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2146577096
Cited by
51
References
1
FWCI
6.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type. https://app.cochat.ai/papers/10.1186/1476-4598-12-11
The paper
Rust, S., Guillard, S., Sachsenmeier, K., Hay, C., Davidson, M., Karlsson, A., Karlsson, R., Brand, E., Lowne, D., Elvin, J., Flynn, M., Kurosawa, G., Hollingsworth, R., Jermutus, L., & Minter, R. (2013). Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type. Molecular Cancer. https://doi.org/10.1186/1476-4598-12-11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.